Protocol CY 4031: A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tiramsemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS)

Trial ID or NCT#

NCT02496767

Status

recruiting iconRECRUITING

Purpose

To assess the safety, tolerability, and efficacy of the study medication, Tirasemtiv, in ALS.

Investigator(s)

Yuen So, MD, PhD

Contact us to find out if this trial is right for you.

Contact

Bona Park Purse